An Observational Study Evaluating the Long-Term Safety and Immunogenicity of HEPLISAV Compared With Engerix-B in Adults With Chronic Kidney Disease Who Have Previously Received At Least One Hepatitis B Vaccine Series

Trial Profile

An Observational Study Evaluating the Long-Term Safety and Immunogenicity of HEPLISAV Compared With Engerix-B in Adults With Chronic Kidney Disease Who Have Previously Received At Least One Hepatitis B Vaccine Series

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jul 2014

At a glance

  • Drugs V 270 (Primary) ; Hepatitis B vaccine recombinant
  • Indications Hepatitis B
  • Focus Pharmacodynamics; Registrational
  • Sponsors Dynavax Technologies
  • Most Recent Events

    • 16 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 28 Mar 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2010-022372-31).
    • 28 Mar 2012 Trial phase III identified as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top